Inozyme Pharma Inc. (INZY)
1.48
-0.03 (-1.99%)
At close: Jan 15, 2025, 10:37 AM
Company Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases.
The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis.
It has a license agreement with Yale University for specified therapeutic and prophylactic products.
Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Inozyme Pharma Inc.
| Country | United States |
| IPO Date | Jul 24, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Dr. Douglas A. Treco Ph.D. |
Contact Details
Address: 321 Summer Street Boston, Massachusetts United States | |
| Website | https://www.inozyme.com |
Stock Details
| Ticker Symbol | INZY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001693011 |
| CUSIP Number | 45790W108 |
| ISIN Number | US45790W1080 |
| Employer ID | 47-5129768 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer & Chairman |
| Dr. Matthew Winton Ph.D. | Senior Vice President & Chief Operating Officer |
| Gayle Gironda | Senior Vice President & Chief People Officer |
| Sanjay S. Subramanian M.B.A., M.S. | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Corporate Secretary |
| Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director |
| Dr. David Thompson M.A., M.S., Ph.D. | Senior Vice President, Chief Scientific Officer & Chief Development Officer |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer |
| Dr. Soojin Kim Ph.D. | Senior Vice President & Chief Technical Operations Officer |
| Dr. Yves Sabbagh Ph.D. | Chairman of Scientific Advisory Board & Senior Vice President |
| Stefan Riley | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 10, 2025 | 8-K | Current Report |
| Dec 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 05, 2024 | 10-Q | Quarterly Report |
| Nov 05, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 07, 2024 | 4 | Filing |
| Oct 07, 2024 | 3 | Filing |